DiaMedica Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMAC research report →
About the company
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes.
- CEO
- Dietrich John Pauls
- IPO
- 2012
- Employees
- 27
- HQ
- Minneapolis, MN, US
Price Chart
- Market Cap
- $410.59M
- P/E
- -10.73
- P/S
- 0.00
- P/B
- 8.68
- EV/EBITDA
- -11.59
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.09%
- ROIC
- -77.42%
- Revenue
- $0 · 0.00%
- Net Income
- $-32,766,000 · -34.05%
- EPS
- $-0.70 · -16.67%
- Op Income
- $-34,397,000
- FCF YoY
- -31.68%
- 52W High
- $10.42
- 52W Low
- $3.57
- 50D MA
- $6.12
- 200D MA
- $7.17
- Beta
- 1.00
- Avg Volume
- 194.18K
Get TickerSpark's AI analysis on DMAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | Parsons James T. | other | 10,095 |
| Jan 2, 26 | Giuffre Randall Michael | other | 6,175 |
| Jan 2, 26 | Semba Charles Pauling | other | 3,355 |
| Nov 25, 25 | STAHLBERG JAN | buy | 73,099 |
| Nov 24, 25 | STAHLBERG JAN | buy | 40,253 |
| Nov 21, 25 | STAHLBERG JAN | buy | 208,872 |
| Nov 20, 25 | STAHLBERG JAN | buy | 128,426 |
| Nov 19, 25 | STAHLBERG JAN | buy | 240,352 |
| Nov 18, 25 | STAHLBERG JAN | buy | 182,882 |
| Nov 17, 25 | STAHLBERG JAN | buy | 187,393 |
Our DMAC coverage
Recent articles, reports, and earnings notes.
No research on DMAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMAC report →Similar companies
Peers in the same neighborhood.